Sector News

A vibrating pill for constipation heads to the FDA after completing phase 3 study

May 29, 2022
Life sciences

A small, vibrating pill designed to help people with chronic constipation cleared a clinical study and is headed to the FDA for final review.

Vibrant Gastro is putting forward its approach as a drug-free alternative for infrequent or difficult bowel movements.

Swallowed along with a glass of water, the disposable pill—about the size of an everyday multivitamin—aims to do more than simply shake up any possible blockages. The device is designed to also help reset the connection between the gut and the brain’s circadian rhythm.

As it travels through the digestive system, its vibrations help stimulate the colon’s involuntary contractions, with the ultimate goal of resyncing them with the body’s biological clock to improve regular bowel movements after one to eight weeks of use. The pill’s progress can also be tracked via a companion smartphone app.

Among 312 participants, 39% reported at least one additional complete bowel movement per week, compared to 22% of those given a placebo pill. Over 22% logged two or more, versus 11% in the control group.

The study also recorded no severe side effects, including treatment-related diarrhea or nausea, according to the company. At the same time, the data also showed improvements in stool consistency and reported quality of life.

“The goal of Vibrant is to address a significant unmet treatment problem in chronic constipation, which has made life very challenging for those who suffer from it,” said Satish Rao, M.D., Ph.D., a professor of medicine at Augusta University, who was one of the primary investigators of a phase 3 study presented at the annual Digestive Disease Week conference.

Israel-based Vibrant estimates that as many as 35 million people in the U.S. suffer from chronic constipation. The company raised $7.5 million in a March 2021 series E round led by Unorthodox Ventures.

By Conor Hale

Source: fiercebiotech.com

comments closed

Related News

May 26, 2024

From pharma to food: Vitafoods 2024 highlights

Life sciences

Beyond the vibrant displays and insightful discussions at Vitafoods 2024 stood the backdrop of a rapidly expanding nutraceutical market. With consumers increasingly seeking preventive healthcare solutions and natural alternatives to traditional medicine, the global nutraceutical industry has witnessed remarkable growth in recent years.

May 26, 2024

Genmab completes acquisition of ProfoundBio

Life sciences

Genmab has completed its $1.8 billion acquisition of ProfoundBio, a clinical-stage biotechnology company developing next-generation antibody-drug conjugates (ADC)s and ADC technologies for the treatment of cancers.

May 26, 2024

Merck to acquire life science company Mirus Bio

Life sciences

Merck has agreed to acquire US life sciences company Mirus Bio for $600 million (around €550 million) from Gamma Biosciences, a life sciences platform established by global investment firm KKR. Based in Madison, Wisconsin, Mirus Bio is a specialist in the development and commercialization of transfection reagents.

How can we help you?

We're easy to reach